Quarterly ResultMay 11, 2026, 04:14 PM
Gain Therapeutics Q1 Net Loss $0.13/share; GT-02287 Progress
AI Summary
Gain Therapeutics reported its financial results for the first quarter ended March 31, 2026, with a net loss of $0.13 per share, an improvement from $0.16 per share in the prior year. The company also provided a corporate update, highlighting promising biomarker and early clinical evidence from its ongoing Phase 1b study of GT-02287 for Parkinson's disease, including an 81% average decrease in GluSph levels and stable MDS-UPDRS scores. Gain Therapeutics anticipates FDA IND clearance for GT-02287 in Q2 2026 and expects to commence its Phase 2 study in Q3 2026.
Key Highlights
- Net loss per share improved to $0.13 in Q1 2026 from $0.16 in Q1 2025.
- Research and development expenses increased to $2.8 million in Q1 2026 from $2.3 million in Q1 2025.
- Cash, cash equivalents, and marketable securities were $16.5 million as of March 31, 2026.
- GT-02287 Phase 1b showed an 81% average decrease in GluSph and stable MDS-UPDRS scores.
- FDA IND clearance for GT-02287 is expected in Q2 2026.
- Phase 2 clinical trial for GT-02287 is expected to begin in Q3 2026.
- Advanced lead GT-04686 is ready for IND-enabling studies for Parkinson's disease.